SCHEMBL1574850

SCHEMBL1574850

CCc1ccccc1NC(=O)N1CC(N(CC)CC)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.54
MAPT P10636 1/20 0.48
KMT2A Q03164 3/20 0.46
THRB P10828 1/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 2/20 0.44
TP53 P04637 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
TSHR P16473 1/20 0.43
TRPV1 Q8NER1 1/20 0.43
POLB P06746 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575666 0.90 TAAR1 (0.52) TAAR1MAPTKMT2ATHRBKDM4E
SCHEMBL1576522 0.88 TAAR1 (0.51) TAAR1MAPTKMT2ATHRBKDM4E
SCHEMBL1574672 0.87 TAAR1 (0.50) TAAR1MAPTKMT2ATHRBKDM4E
SCHEMBL1574669 0.86 GAA (0.51) KMT2AKDM4ELMNA
SCHEMBL1574839 0.85 GAA (0.55) MAPTKMT2AKDM4ELMNATP53
SCHEMBL1574831 0.85 KDM4E (0.64) MAPTKMT2AKDM4ETP53TAS1R3
SCHEMBL1574665 0.85 TAAR1 (0.50) TAAR1MAPTKMT2ATHRBKDM4E
SCHEMBL1574903 0.84 TAAR1 (0.52) TAAR1MAPTKMT2ATHRBKDM4E
SCHEMBL1574623 0.83 TAAR1 (0.51) TAAR1MAPTKMT2ATHRBKDM4E
SCHEMBL1574440 0.83 KDM4E (0.60) TAAR1KMT2AKDM4ELMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB TAAR1 2118/4885MAPT 3908/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.